Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) Return on Capital Employed (2020 - 2026)

C4 Therapeutics has reported Return on Capital Employed over the past 7 years, most recently at 35.94% for Q1 2026.

  • For Q1 2026, Return on Capital Employed rose 374.0% year-over-year to 35.94%; the TTM value through Mar 2026 reached 35.94%, up 374.0%, while the annual FY2025 figure was 35.86%, 177.0% up from the prior year.
  • Return on Capital Employed for Q1 2026 was 35.94% at C4 Therapeutics, up from 41.26% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 20.04% in Q1 2022 and troughed at 52.96% in Q3 2025.
  • A 5-year average of 37.12% and a median of 37.66% in 2024 define the central range for Return on Capital Employed.
  • Biggest five-year swings in Return on Capital Employed: tumbled -2140bps in 2023 and later soared 762bps in 2024.
  • Year by year, Return on Capital Employed stood at 32.26% in 2022, then crashed by -38bps to 44.57% in 2023, then increased by 16bps to 37.66% in 2024, then dropped by -10bps to 41.26% in 2025, then rose by 13bps to 35.94% in 2026.
  • Business Quant data shows Return on Capital Employed for CCCC at 35.94% in Q1 2026, 41.26% in Q4 2025, and 52.96% in Q3 2025.